Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Cloudberry (Rubus chamaemorus) is a Nordic berry rich in ellagic acid, anthocyanins, and Vitamin C. It has an excellent safety profile as a food ingredient. No significant drug interactions or adverse effects documented at supplemental doses. May have mild antiplatelet activity due to quercetin content; caution with anticoagulant therapy at high supplemental doses.
Biological and Chemical Classification
- Scientific Name
- Rubus chamaemorus
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Cloudberry indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 აპრ 2026, 12:10
Evidence Distribution
-
Observational / other LOW evidence YELLOWThe origin of the octoploid cloudberry (Rubus chamaemorus) genome is the result of multiple and complex polyploidization events. ↗Strand MA et al.. The origin of the octoploid cloudberry (Rubus chamaemorus) genome is the result of multiple and complex polyploidization events.. J Hered. 2026. PMID:41879285.PMID 41879285 ↗Journal J HeredYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41879285/
-
Observational / other LOW evidence YELLOWContrasting effects of experimental warming in the initiation year and the flowering year on flower phenology of boreal understory species. ↗Mulder CPH et al.. Contrasting effects of experimental warming in the initiation year and the flowering year on flower phenology of boreal understory species.. Am J Bot. 2026. PMID:41670238.PMID 41670238 ↗Journal Am J BotYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41670238/
-
Observational / other LOW evidence YELLOWAnalysis of pentacyclic triterpenoids and phytosterols in cloudberry (Rubus chamaemorus L.) by LC-MS/MS. ↗Falev DI et al.. Analysis of pentacyclic triterpenoids and phytosterols in cloudberry (Rubus chamaemorus L.) by LC-MS/MS.. Nat Prod Res. 2026. PMID:39428696.PMID 39428696 ↗Journal Nat Prod ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39428696/
-
Observational / other LOW evidence YELLOWDetermination of Carotenoids and Their Antioxidant Activity in Fruits of Selected Species from the Genus Rubus and Their Cultivars and Hybrids from… ↗Adamczuk N et al.. Determination of Carotenoids and Their Antioxidant Activity in Fruits of Selected Species from the Genus Rubus and Their Cultivars and Hybrids from Poland Versus Other Regions of the World.. Antioxidants (Basel). 2025. PMID:41462639.PMID 41462639 ↗Journal Antioxidants (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41462639/
-
Observational / other LOW evidence YELLOWGold from nature's pantry: a diachronic study of Rubus chamaemorus L. (Rosaceae) in swedish gastronomy and economy. ↗Svanberg I et al.. Gold from nature's pantry: a diachronic study of Rubus chamaemorus L. (Rosaceae) in swedish gastronomy and economy.. J Ethnobiol Ethnomed. 2025. PMID:41457281.PMID 41457281 ↗Journal J Ethnobiol EthnomedYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41457281/
-
Observational / other LOW evidence YELLOWCloudberry-derived nanovesicles as stable oral drug delivery systems: gastrointestinal stability and age-related biodistribution in mice. ↗Shanthi KB et al.. Cloudberry-derived nanovesicles as stable oral drug delivery systems: gastrointestinal stability and age-related biodistribution in mice.. Nanoscale. 2025. PMID:40878163.PMID 40878163 ↗Journal NanoscaleYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40878163/
-
Observational / other LOW evidence YELLOWAcclimation of subarctic vegetation to warming and increased cloudiness. ↗Ndah FA et al.. Acclimation of subarctic vegetation to warming and increased cloudiness.. Plant Environ Interact. 2024. PMID:38323130.PMID 38323130 ↗Journal Plant Environ InteractYear 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/38323130/
-
Observational / other LOW evidence YELLOWThe Role of the Hercynian Mountains of Central Europe in Shaping Plant Migration Patterns in the Pleistocene-A Review. ↗Urbaniak J et al.. The Role of the Hercynian Mountains of Central Europe in Shaping Plant Migration Patterns in the Pleistocene-A Review.. Plants (Basel). 2023. PMID:37765481.PMID 37765481 ↗Journal Plants (Basel)Year 2023Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/37765481/
-
Observational / other LOW evidence YELLOWReduction of methicillin-resistant Staphylococcus aureus biofilm growth and development using arctic berry extracts. ↗Aguilera-Correa JJ et al.. Reduction of methicillin-resistant Staphylococcus aureus biofilm growth and development using arctic berry extracts.. Front Cell Infect Microbiol. 2023. PMID:37424779.PMID 37424779 ↗Journal Front Cell Infect MicrobiolYear 2023Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/37424779/
-
Observational / other LOW evidence YELLOWComprehensive Characterization of Secondary Metabolites in Fruits and Leaves of Cloudberry (Rubus chamaemorus L.). ↗Faleva AV et al.. Comprehensive Characterization of Secondary Metabolites in Fruits and Leaves of Cloudberry (Rubus chamaemorus L.).. Metabolites. 2023. PMID:37233639.PMID 37233639 ↗Journal MetabolitesYear 2023Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/37233639/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Cloudberry. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Cloudberry
A score of 1.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.